

## Anti-CEACAM1

Catalog No.	Description
<b>AR909-5RE</b>	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
<b>AR909-10RE</b>	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems
<b>PU909-UPE</b>	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
<b>PU909-5UPE</b>	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
<b>PU909-1UPE</b>	0.1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
<b>AW909-YCDE</b>	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 160 tests
<b>AW909-50DE</b>	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 50 tests

Clone	Species	Ig Class
Polyclonal	Rabbit	IgG

### Intended Use

**For In Vitro Diagnostic Use.** This antibody is designed for the specific localization of CEACAM1 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

### Summary and Explanation

CEACAM1 (Carcinoembryonic antigen-related cell adhesion molecule 1) also known as biliary glycoprotein and CD66a is a trans-membrane multifunctional cell adhesion molecule and a member of the immunoglobulin superfamily. CEACAM1 is broadly expressed in many epithelial, endothelial, and hematopoietic cells such as monocytes and natural killer cells and has been shown to play a role in multiple cellular activities including differentiation, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses. CEACAM1 is important to tumor development and altered CEACAM1 expression has been reported in many cancers including metastatic melanoma, osteosarcoma and lung cancer.

### Storage and Handling

**Store at 2-8°C.** Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

### Principles of the Procedure

Antigen detection by immunohistochemistry (**IHC**) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The **primary antibody** may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

### Reagents Provided

Rabbit Polyclonal Antibody CEACAM1 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

### Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

### Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	COLON CARCINOMA tissue as available with Biogenex FB-909PE* & FG-909PE*
Recommended Dilution for Concentrated Antibody	<b>1:50-100 in HK941</b>
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)
Recommended Pretreatment (Xmatrx)	EZ-AR2 Elegance (HX032-YCD)
Antibody Incubation (Manual/i6000)	30-60 mins at RT
Antibody Incubation (Xmatrx)	30-60 mins at RT
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step <b>OR</b> One-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB; see p. 2 for more

<b>Category</b>	Antibodies	<b>Revision No.</b>	F
<b>Document No.</b>	932-909P-EN	<b>Release Date</b>	30-May-2024

	information
--	-------------

\*FB: positive control barrier slides, FG: positive control non-barrier slides. Xmatrx requires barrier slides.

\*\*Pretreatment times will vary based on individual microwave power.

\*\*\*For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440-XAKE (1000 Test)	QD630-XAKE (1000 Test)	QP300-XAKE (1000 Test)
	QD430-XAKE (1000 Test)		
	QD420-YIKE (500 Test)	QD620-XAKE (500 Test)	QP900-9LE (500 Test)
	QD400-60KE (60 Test)		
Xmatrx - Automation	QD550-YCDE (200 Test)	QD610-YADE (200 Test)	N/A
i6000 - Automation	QD410-YAXE (200 Test)	QD610-YAXE (200 Test)	N/A
For more information, visit <a href="http://www.biogenex.com">www.biogenex.com</a> .			

### Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

### Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

### Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or [support@biogenex.com](mailto:support@biogenex.com) or your local distributor to report unusual staining.

### Expected Results

This antibody stains membrane & cytoplasm in positive cells in formalin-fixed, paraffin embedded tissue sections. An example

image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

### Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

### Bibliography

- Entrez Gene: CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)
- Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. *Nat Rev Immunol.* 6 433–46 (2006).
- Li C, Chen CJ, Shively JE. Mutational analysis of the cytoplasmic domain of CEACAM1-4L in humanized mammary glands reveals key residues involved in lumen formation: stimulation by Thr-457 and inhibition by Ser-461. *Exp Cell Res.* 315 (7) 1225–33 (2009).
- Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. *Cancer Metastasis Rev.* 32 (3-4) 643–71 (2013).
- Fiori V, Magnani M, Cianfriglia M. The expression and modulation of CEACAM1 and tumor cell transformation. *Ann Ist Super Sanita.* 48 (2) 161–171 (2012).

	Temperature Limitation	<b>IVD</b>	In Vitro Diagnostic Medical Device
	Use By Date	<b>LOT</b>	Batch Code
	Non-Sterile		Consult Instructions for Use
	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	F
Document No.	932-909P-EN	Release Date	30-May-2024